GlassScriptPhysician profile
Anna L Castro
NPI 1841744315
$183,974.91
in general payments reported to CMS, 2019-2025
50 companies · $57K in 2025
The $57K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14K · 2022: $34K · 2023: $38K · 2024: $41K · 2025: $57K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $82K · Honoraria: $17K · Consulting Fee: $16K · Travel and Lodging: $12K · Food and Beverage: $8,860 · Education: $201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $82,326.25 |
| Honoraria | $16,780.00 |
| Consulting Fee | $15,745.59 |
| Travel and Lodging | $11,583.08 |
| Food and Beverage | $8,860.06 |
| Education | $201.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $117,484.82 | 2021-2025 | |
| Lundbeck LLC | $24,969.11 | 2021-2025 | Vyepti |
| Impel Pharmaceuticals INC. | $12,897.07 | 2022-2023 | Trudhesa |
| Axsome Therapeutics, INC. | $8,886.57 | 2025 | Symbravo |
| Biogen, INC. | $7,173.51 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $2,479.20 | 2021-2025 | Ajovy |
| Emd Serono, INC. | $2,283.51 | 2021 | |
| Celgene Corporation | $1,337.68 | 2021 | |
| Pfizer INC. | $1,244.32 | 2023-2025 | |
| Amgen INC. | $807.71 | 2021-2024 | Aimovig |
| Novartis Pharmaceuticals Corporation | $508.49 | 2021-2023 | |
| Lilly USA, LLC | $492.65 | 2021-2024 | Emgality, Reyvow |
| Horizon Therapeutics Plc | $300.25 | 2021-2023 | Uplizna |
| Allergan, INC. | $286.26 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $216.61 | 2022 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Castro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.